Axsome Therapeutics, Inc. (AXSM) News
Filter AXSM News Items
AXSM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AXSM News Highlights
- AXSM's 30 day story count now stands at 3.
- Over the past 4 days, the trend for AXSM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AXSM are DEC, CNS and LLY.
Latest AXSM News From Around the Web
Below are the latest news stories about AXSOME THERAPEUTICS INC that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual MeetingNew data on Auvelity’s impact on quality of life, measured by the Q-LES-Q-SF, in patients who had received at least one prior treatment during their current depressive episode Data on Auvelity exploring reduction of depressive symptoms regardless of a patient’s interest-activity symptom severity NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (C |
3 Unstoppable Stocks to Buy Right NowHere's why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Axsome Therapeutics): One promising growth stock that investors may be overlooking today is Axsome Therapeutics. With a market capitalization of around $3.2 billion, this is still a fairly small biotech stock for investors to load up on before it gets much bigger. |
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders TodayNEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is hosting a virtual investor event and conference call today from 8 a.m. – 10 a.m. Eastern Time to provide an update on solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and trace amine-associated receptor 1 (TAAR1) agonist. At the event, invited ph |
11 Best Upside Stocks To Buy Right NowIn this piece, we will take a look at the 11 best upside stocks to buy right now. If you want to skip our overview of share valuation, then take a look at the 5 Best Upside Stocks To Buy Now. The art of buying shares on the market has always gone hand in hand […] |
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7NEW YORK, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a virtual event on December 7 from 8 a.m. - 10 a.m. Eastern Time to provide investors an update on its development programs for solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) |
3 Biotech Stocks That Could Be Millionaire MakersIn my view, these three players, held as part of a diversified portfolio, could be millionaire makers. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge moment in its story as a company. Along with partner Vertex Pharmaceuticals, it earned the world's first authorization for a gene-editing treatment that uses the "CRISPR technique." |
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceNEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, Nov. 28, 2023, from 9:30 a.m. - 9:55 a.m. Eastern Time at the Lotte New York Palace in New York City. |
3 Growth Stocks to Buy Right Now Without Any HesitationThree Motley Fool contributors have identified growth stocks they think can be bought right now without any hesitation. Here's why they picked AbbVie (NYSE: ABBV), Axsome Therapeutics (NASDAQ: AXSM), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (AbbVie): One underrated stock that investors appear to be discounting too heavily right now is AbbVie. |
3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest RatesLast year, the Federal Reserve began hiking interest rates in an effort to slow down the economy. Today, interest rates are at their highest levels since the early 2000s. For many businesses, an increase in interest rates has led to investors feeling less bullish on their stocks as borrowing costs rise and growth becomes more difficult. |
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass EstimatesAxsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement. |